Agios Pharmaceuticals (AGIO) Depreciation & Amortization (CF) (2012 - 2026)

Agios Pharmaceuticals has reported Depreciation & Amortization (CF) for 15 years, with the latest figure at $1.4 million in Q1 2026.

• For the quarter ending Q1 2026, Depreciation & Amortization (CF) rose 6.65% year-over-year to $1.4 million; the trailing twelve-month figure through Mar 2026 stood at $5.3 million (down 5.75% YoY), and the FY2025 full-year result was $5.2 million, down 8.42% from the prior year.
• Depreciation & Amortization (CF) for Q1 2026 stood at $1.4 million, up from $1.3 million in the prior quarter.
• The five-year high for Depreciation & Amortization (CF) was $2.5 million in Q1 2022, with the low at $1.3 million in Q2 2025.
• Historically, Depreciation & Amortization (CF) has averaged $1.6 million across 5 years, with a median of $1.4 million in 2023.
• Annual changes were most pronounced in 2023 — Depreciation & Amortization (CF) declined 27.76% — and 2026, when it grew 6.65%.
• Agios Pharmaceuticals' Depreciation & Amortization (CF) stood at $1.8 million in 2022, then declined by 22.66% to $1.4 million in 2023, then retreated by 2.57% to $1.4 million in 2024, then declined by 7.39% to $1.3 million in 2025, then rose by 7.66% to $1.4 million in 2026.
• The last three Depreciation & Amortization (CF) figures came in at $1.4 million (Q1 2026), $1.3 million (Q4 2025), and $1.4 million (Q3 2025), per Business Quant data.